Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (NASDAQ: EDS) in patients aged seven years and older with narcolepsy. The company’s shares rose 5.1% on the news. The stock fell 1.4% year to date compared with the industry’s 0.7% decline. Image Source: Zacks Investment Research Label Expansion Of AVDL’s LumryzLumryz is a once-at-bedtime formulation extended-release sodium oxybate….